News & Updates

A red magnifying glass.

ACOG article 2.4

ACOG article 2.4

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.4

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA_1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Adalimumab concentrations negatively linked to inflammatory markers in RA

Adalimumab concentrations negatively linked to inflammatory markers in RA

A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.

Adalimumab concentrations negatively linked to inflammatory markers in RA

22 Jul 2024

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Use of cycline antibiotics (CAs) is associated with an elevated risk of pseudotumour cerebri syndrome (PTCS) or papilledema, suggests a recent study. However, no statistically significant link between CA use and PTCS development is seen when accounting for confounding factors.

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

17 Jul 2024

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

10 Jul 2024

ACOG article 2.6

ACOG article 2.6

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.6

ACOG article 2.1

ACOG article 2.1

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.1

ACOG article 2.7

ACOG article 2.7

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.7

Something went wrong.